Temozolomide and oral etoposide in children with recurrent malignant brain tumors
Despite advances in the treatment of brain tumors, the prognosis of children with recurrent malignant brain tumors remains poor. Etoposide (VP-16), an inhibitor of nuclear enzyme deoxyribonucleic acid (DNA)-topoisomerase II, has shown activity in brain tumors. Its efficacy appears schedule dependent...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2020-06-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://www.drugsincontext.com/temozolomide-and-oral-etoposide-in-children-with-recurrent-malignant-brain-tumors |
id |
doaj-f3a1f3c90cfe49589441c96ee72f6bf6 |
---|---|
record_format |
Article |
spelling |
doaj-f3a1f3c90cfe49589441c96ee72f6bf62020-11-25T03:24:40ZengBioExcel Publishing LtdDrugs in Context1740-43981740-43982020-06-0191910.7573/dic.2020-3-1Temozolomide and oral etoposide in children with recurrent malignant brain tumorsAntonio RuggieroAnna ArianoSilvia TriaricoMichele Antonio CapozzaAlberto RomanoPalma MauriziStefano MastrangeloGiorgio AttinàDespite advances in the treatment of brain tumors, the prognosis of children with recurrent malignant brain tumors remains poor. Etoposide (VP-16), an inhibitor of nuclear enzyme deoxyribonucleic acid (DNA)-topoisomerase II, has shown activity in brain tumors. Its efficacy appears schedule dependent but, to date, the most effective schedule of administration has not been well defined. Temozolomide (TMZ), like VP-16, penetrates the blood–brain barrier and has activity against malignant brain tumors. This novel alkylating agent is rapidly absorbed and is highly bioavailable after oral administration. The antitumor activity of TMZ has been shown to be schedule dependent. Based on the evidence of different mechanisms of cytotoxicity, TMZ and VP-16 have been utilized in combination in patients with malignant brain tumors. This review evaluates the results derived from the combination use of TMZ and oral VP-16. The reported data suggest potential activity of oral VP-16 and TMZ alone or in combination. Further clinical trials are needed to explore and confirm their promising activity in relapsed brain neoplasms.https://www.drugsincontext.com/temozolomide-and-oral-etoposide-in-children-with-recurrent-malignant-brain-tumorsetoposidegliomamedulloblastomarecurrent brain tumortemozolomide |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Antonio Ruggiero Anna Ariano Silvia Triarico Michele Antonio Capozza Alberto Romano Palma Maurizi Stefano Mastrangelo Giorgio Attinà |
spellingShingle |
Antonio Ruggiero Anna Ariano Silvia Triarico Michele Antonio Capozza Alberto Romano Palma Maurizi Stefano Mastrangelo Giorgio Attinà Temozolomide and oral etoposide in children with recurrent malignant brain tumors Drugs in Context etoposide glioma medulloblastoma recurrent brain tumor temozolomide |
author_facet |
Antonio Ruggiero Anna Ariano Silvia Triarico Michele Antonio Capozza Alberto Romano Palma Maurizi Stefano Mastrangelo Giorgio Attinà |
author_sort |
Antonio Ruggiero |
title |
Temozolomide and oral etoposide in children with recurrent malignant brain tumors |
title_short |
Temozolomide and oral etoposide in children with recurrent malignant brain tumors |
title_full |
Temozolomide and oral etoposide in children with recurrent malignant brain tumors |
title_fullStr |
Temozolomide and oral etoposide in children with recurrent malignant brain tumors |
title_full_unstemmed |
Temozolomide and oral etoposide in children with recurrent malignant brain tumors |
title_sort |
temozolomide and oral etoposide in children with recurrent malignant brain tumors |
publisher |
BioExcel Publishing Ltd |
series |
Drugs in Context |
issn |
1740-4398 1740-4398 |
publishDate |
2020-06-01 |
description |
Despite advances in the treatment of brain tumors, the prognosis of children with recurrent malignant brain tumors remains poor. Etoposide (VP-16), an inhibitor of nuclear enzyme deoxyribonucleic acid (DNA)-topoisomerase II, has shown activity in brain tumors. Its efficacy appears schedule dependent but, to date, the most effective schedule of administration has not been well defined. Temozolomide (TMZ), like VP-16, penetrates the blood–brain barrier and has activity against malignant brain tumors. This novel alkylating agent is rapidly absorbed and is highly bioavailable after oral administration. The antitumor activity of TMZ has been shown to be schedule dependent. Based on the evidence of different mechanisms of cytotoxicity, TMZ and VP-16 have been utilized in combination in patients with malignant brain tumors. This review evaluates the results derived from the combination use of TMZ and oral VP-16. The reported data suggest potential activity of oral VP-16 and TMZ alone or in combination. Further clinical trials are needed to explore and confirm their promising activity in relapsed brain neoplasms. |
topic |
etoposide glioma medulloblastoma recurrent brain tumor temozolomide |
url |
https://www.drugsincontext.com/temozolomide-and-oral-etoposide-in-children-with-recurrent-malignant-brain-tumors |
work_keys_str_mv |
AT antonioruggiero temozolomideandoraletoposideinchildrenwithrecurrentmalignantbraintumors AT annaariano temozolomideandoraletoposideinchildrenwithrecurrentmalignantbraintumors AT silviatriarico temozolomideandoraletoposideinchildrenwithrecurrentmalignantbraintumors AT micheleantoniocapozza temozolomideandoraletoposideinchildrenwithrecurrentmalignantbraintumors AT albertoromano temozolomideandoraletoposideinchildrenwithrecurrentmalignantbraintumors AT palmamaurizi temozolomideandoraletoposideinchildrenwithrecurrentmalignantbraintumors AT stefanomastrangelo temozolomideandoraletoposideinchildrenwithrecurrentmalignantbraintumors AT giorgioattina temozolomideandoraletoposideinchildrenwithrecurrentmalignantbraintumors |
_version_ |
1724600681558441984 |